araag2/HINT huggingface dataset:
Clinical trial NCT01288443 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: alirocumab, placebo (for alirocumab), atorvastatin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  Participants with primary hypercholesterolemia receiving a lipid-lowering treatment
             other than atorvastatin or not at stable dose of atorvastatin 10 mg, 20 mg, or 40 mg
             for at least 6 weeks prior to screening period or drug naive participants if they are
             likely to have low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (≥ 2.59 mmol/L)
             at the end of the 6-week run-in treatment period on atorvastatin therapy

        OR

          -  Participants with primary hypercholesterolemia treated with atorvastatin at stable
             dose of 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to screening period and
             likely to have LDL-C ≥ 100 mg/dL (≥ 2.59 mmol/L) at the screening visit

        Exclusion criteria:

          1. LDL-C < 100 mg/dL (< 2.59 mmol/L):

               -  After the run-in period on atorvastatin (10 mg, 20 mg, or 40 mg) for participants
                  receiving a lipid-lowering treatment other than atorvastatin or not at stable
                  dose of atorvastatin 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to the
                  screening, or drug naive participant

             OR

               -  At the first visit for participants who were being treated with stable dose of
                  atorvastatin (10 mg, 20 mg, or 40 mg) for at least 6 weeks prior to screening

          2. Participants not previously instructed on a cholesterol-lowering diet

          3. Participants with type 1 diabetes

          4. Participants with type 2 diabetes treated with insulin

          5. Participants with type 2 diabetes and with an glycated hemoglobin (HbA1c) ≥ 8.5% at
             screening visit (considered poorly controlled)

          6. Laboratory findings measured before randomization:

               -  Triglycerides (TG) > 350 mg/dL (> 3.95 mmol/L) at screening visit

               -  Positive serum or urine pregnancy test in females of childbearing potential

          7. Pregnant or breast-feeding women

          8. Women of childbearing potential with no effective contraceptive method

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT01200394 (phase 2, status: completed)
Conditions: diabetic nephropathies
ICD codes: H35.23, Z86.31, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: pf-00489791, placebo
SMILES: CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects greater than or equal to 18 years. Female subjects must be of
             non-child bearing potential.

          -  Clinical diagnosis of type 2 diabetes together with stages 3a, 3b or 4 CKD, based on
             an eGFR of 25-59 mL/min/1.73m2.

          -  Evidence of persistent, overt albuminuria; defined as a UACR greater than or equal to
             300 mg/g (greater than or equal to 33.9 mg/mmol) for greater than 3 months.

        Exclusion Criteria:

          -  Subjects with CKD resulting from type 1 diabetes or non-diabetic CKD.

          -  Subjects with poorly controlled diabetes mellitus, defined as HbA1C >9%.

          -  Subjects on combination ACE inhibitor/ARB therapy.
Clinical trial NCT00679783 (phase 2, status: active, not recruiting)
Conditions: ovarian carcinoma, breast cancer
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: azd2281
SMILES: OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed high grade serous and/or undifferentiated carcinoma of ovary,
             fallopian tube or peritoneum

          -  Oestrogen, progesterone and HER2 negative advanced adenocarcinoma of the breast

          -  Known BRCA positive breast cancer or ovarian cancer, that is not high grade serous or
             undifferentiated tubo-ovarian carcinoma.

          -  Performance status of no more than 2.

        Exclusion Criteria:

          -  Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within
             4 weeks prior to entry

          -  Major surgery with 4 weeks of entering the study and must have recovered from effects
             of any major surgery .
Clinical trial NCT00592098 (phase 2, status: completed)
Conditions: amputation stumps, pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: strontium chloride hexahydrate, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Lower limb amputation at least 6 months prior to inclusion

          -  Presenting with moderate-to-severe pain intensity (above 50 on 100 mm VAS) at
             screening, to be confirmed prior to randomisation as: Mean (over the 14 days run-in
             period) stump API rating above 50 on a 100 mm VAS

          -  Outpatients, aged 18 years and above

          -  Written informed consent

        Exclusion Criteria:

          -  Subjects who have received treatment with any potent opioid in the 4 weeks prior to
             study entry (i.e. an opioid assumed to cause abstinence symptoms upon abrupt
             cessation)

          -  Subjects taking any analgesic medication (except for rescue medication as defined in
             this protocol)

          -  Subjects with expressed dissatisfaction with their prosthesis comfort

          -  Pregnant or breast-feeding women

          -  Any malignant disease

          -  Subjects who have received an investigational drug or used an investigational device
             in the 30 days prior to study entry.

          -  Subjects unable to comply with the study assessments

          -  Subjects with documented or suspected alcohol or drug abuse
Clinical trial NCT00584870 (phase 2, status: completed)
Conditions: low back pain
ICD codes: M54.50, M54.51, M54.59
Drugs: naproxen, placebo, pf-04383119 (rn624)
SMILES: COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female of any race, >18 years of age and have BMI ≤39 kg/m2

          -  Present with duration of chronic low back pain of ≥3 months requiring regular use of
             analgesic medication (>4 days per week for the past month)

          -  Primary location of low back pain is between the 12th thoracic vertebra and the lower
             gluteal folds, with or without radiation into the posterior thigh, classified as
             Category 1 or 2 according to the classification of the Quebec Task Force in Spinal
             Disorders

          -  Must have a score of ≥4 for Low Back Pain Intensity (NRS) while on current treatment
             at Screening, and completes at least 4 daily pain diaries during the 5 days prior to
             Randomization, with an average Low Back Pain Intensity (NRS) score of ≥4

        Exclusion Criteria:

          -  Back pain due to visceral disorder (i.e. endometriosis) or Back pain due to recent
             major trauma (i.e. vertebral fracture, post-traumatic spondylolisthesis)

          -  History of lumbosacral radiculopathy, spinal stenosis associated with neurological
             impairment, or neurogenic claudication

          -  Osteoporotic compression fracture within the last 6 months

          -  Known history of: Rheumatoid arthritis; Seronegative spondyloarthropathy (i.e.,
             ankylosing spondylitis, psoriatic arthritis, reactive arthritis, inflammatory bowel
             disease-related arthropathy); Paget's disease of spine, pelvis or femur; Fibromyalgia;
             Tumors or infections of the spinal cord

          -  Patients receiving acetaminophen only to manage their chronic low back pain

          -  Any uncontrolled or untreated chronic disease
Clinical trial NCT01497119 (phase 2, status: terminated)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: jnj-39758979, 300 mg, jnj-39758979, 100 mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    this study was terminated prematurely due to 2 cases of agranulocytosis.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of atopic dermatitis based on the criteria of the Japanese Dermatological
             Association and have: pruritus (itching); eczema-like changes in a typical pattern,
             and a chronic or chronically relapsing course.

          -  Childhood onset (under age of 13) of atopic dermatitis.

          -  Diagnosis of moderate atopic dermatitis based on the Rajka Langeland score between 4.5
             and 7.5, inclusive.

          -  Have at least 3 ratings of "Moderate itching", "Severe itching", or "Extremely severe
             itching" either at night or during the day based on the Pruritus Categorical Response
             Scale (PCRS) in the 7 days prior to randomization.

          -  Atopic dermatitis with 10% to 50% (inclusive) Body Surface Area (BSA) involvement.

        Exclusion Criteria:

          -  Have current signs or symptoms of liver or renal insufficiency or cardiac, vascular,
             pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or
             metabolic disturbances that are severe, progressive or uncontrolled in the
             Investigator's opinion. Patients with well controlled asthma, allergic rhinitis, or
             allergic conjunctivitis are allowed to participate. Atopic dermatitis patients with
             other chronic conditions will not be excluded if the Investigator has determined that
             the condition is not severe or progressive and is being controlled with stable
             therapy.

          -  Have any known malignancy or have a history of malignancy (with the exception of basal
             cell carcinoma, squamous cell carcinoma in situ of the skin, or squamous cell
             carcinoma of the skin that has been treated with no evidence of recurrence within 5
             years prior to the first administration of study agent).

          -  Evidence of any other skin condition that, in the opinion of the Investigator, would
             interfere with the assessment of atopic dermatitis.

          -  Use of non-steroid immunosuppressive or immunomodulatory agents within 4 weeks of
             randomization, including cyclosporine A, azathioprine, mycophenolate mofetil, and
             interferon gamma.

          -  Use of systemic corticosteroids within 4 weeks of randomization.
Clinical trial NCT00068666 (phase 2, status: terminated)
Conditions: melanoma (skin), metastatic cancer
ICD codes: C43.51, C43.9, C43.52, D03.51, C43.8, Z85.820, D03.52, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: temozolomide
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage IV malignant melanoma with measurable and unresectable
             disease limited to the central nervous system (CNS)

               -  Study entry within 14 days of diagnosis of brain metastases

          -  Recursive partitioning analysis class I or II

          -  Disease for which no known standard therapy exists that is potentially curative or
             proven capable of extending life expectancy

          -  No meningeal carcinomatosis based on imaging studies or on positive results from CSF
             analysis

          -  No evidence of metastatic disease outside of the CNS

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Karnofsky 70-100%

        Hematopoietic

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 9.0 g/dL

        Hepatic

          -  AST no greater than 3 times upper limit of normal (ULN)

          -  Alkaline phosphatase no greater than 3 times ULN

        Renal

          -  Creatinine no greater than 1.5 times ULN

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No concurrent uncontrolled infection

          -  No other malignancy within the past 5 years except basal cell or squamous cell skin
             cancer treated with local resection only

          -  No prior allergy or intolerance to dacarbazine

          -  No hypersensitivity to temozolomide or any of its components

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 4 weeks since prior biologic therapy

          -  More than 4 weeks since prior immunotherapy

        Chemotherapy

          -  No prior temozolomide

          -  More than 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and
             recovered

        Endocrine therapy

          -  Concurrent steroids allowed if dose stable for at least 7 days prior to CNS imaging

        Radiotherapy

          -  More than 4 weeks since prior radiotherapy

          -  No prior radiotherapy to more than 15% of the bone marrow

          -  No prior radiotherapy to the head and neck area

          -  No prior radiosurgery
Clinical trial NCT00362765 (phase 2/phase 3, status: terminated)
Conditions: type 2 diabetes, dyslipidemia
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: fenofibrate, metformin, placebo
SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was prematurely terminated, due to difficulties in the recruitment of t2dm patients
    who are not under statin therapy at inclusion.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with type 2 diabetes mellitus and dyslipidemia.

        Exclusion Criteria:

          -  Type 1 diabetes.
Clinical trial NCT00004897 (phase 2, status: terminated)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: cisplatin, fluorouracil, hydroxyurea, leucovorin calcium
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC(=O)NO, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1
Reason stopped: 
    institutional review board requested termination - all patients deceased and no new accrual.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically or cytologically proven stage I-III squamous cell
        carcinoma or adenocarcinoma of the esophagus and gastro-esophageal junction
        Unidimensionally measurable disease

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:
        At least 270 days Hematopoietic: WBC greater than 3,000/mm3 Granulocyte count greater than
        1,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin, alkaline phosphatase,
        and SGOT no greater than 2 times upper limit of normal (ULN) Renal: Creatinine less than
        2.0 mg/dL Creatinine clearance greater than 50 mL/min Cardiovascular: No serious
        cardiovascular disease that would preclude study Other: No prior or concurrent malignancy
        within past 5 years except nonmelanoma skin cancer No serious chronic medical illness that
        would preclude study No acute or chronic unresolved infection Not pregnant

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery:
        Not specified
Clinical trial NCT00027508 (phase 2, status: terminated)
Conditions: malignant mesothelioma
ICD codes: C45.9, C45.0, C45.1, C45.2, C45.7
Drugs: trabectedin
SMILES: [H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31
Reason stopped: 
    enrolment halted prematurely and not resumed. 2 patients enrolled. no data was obtained.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed malignant mesothelioma
        that is not amenable to curative surgery At least 1 unidimensionally measurable lesion that
        is at least 15 mm by CT scan OR At least 1 bidimensionally measurable lesion that is at
        least 10 mm by CT scan Lesions in previously irradiated area are not considered measurable
        unless there is evidence of progression No symptomatic brain or leptomeningeal involvement

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 OR Karnofsky 70-100%
        Life expectancy: At least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3
        Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no
        greater than upper limit of normal (ULN) Alkaline phosphatase no greater than ULN unless
        bone metastases are present AST/ALT no greater than 2.5 times ULN Albumin at least 2.5 g/dL
        No chronic active liver disease Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine
        clearance at least 40 mL/min Cardiovascular: No uncontrolled heart disease No uncontrolled
        hypertension Other: Not pregnant or nursing Negative pregnancy test Fertile patients must
        use effective contraception during and for one month after study No other serious illness
        or medical condition No history of significant neurological or psychiatric disorders No
        significant active infection No other concurrent neoplastic disease except non-melanoma
        skin cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prophylactic hematopoietic
        colony-stimulating factors (e.g., filgrastim (G-CSF) or sargramostim (GM-CSF))
        Chemotherapy: No prior systemic chemotherapy No other concurrent chemotherapy Endocrine
        therapy: No concurrent hormonal therapy Radiotherapy: See Disease Characteristics At least
        30 days since prior radiotherapy and recovered No concurrent radiotherapy except palliative
        local radiotherapy to non-target lesions Surgery: See Disease Characteristics At least 14
        days since prior pleurodesis Recovered from prior surgery Other: At least 30 days since
        prior participation in another therapeutic clinical trial or therapy with other
        investigational drugs No concurrent treatment for other neoplastic disease No other
        concurrent experimental anticancer medication
Clinical trial NCT01244763 (phase 2, status: completed)
Conditions: chronic kidney disease, anemia
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0, D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: fg-4592
SMILES: CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12
Eligibility criteria:

        Inclusion Criteria:

          1. Age 18 to 75 years

          2. Chronic kidney disease, not receiving dialysis

          3. Body weight 45 to 140 kg

        Exclusion Criteria:

          1. Any clinically significant infection or evidence of an underlying infection

          2. Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg), or anti-hepatitis C virus antibody (anti-HCV Ab)

          3. History of chronic liver disease

          4. New York Heart Association Class III or IV congestive heart failure

          5. Myocardial infarction or acute coronary syndrome within 12 weeks prior to
             randomization

          6. History of malignancy

          7. Chronic inflammatory disease that could impact erythropoiesis (e.g., systemic lupus
             erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in
             remission

          8. History of myelodysplastic syndrome, multiple myeloma, or pure red cell aplasia

          9. History of hemosiderosis, hemochromatosis or polycystic kidney disease

         10. Active hemolysis or diagnosis of hemolytic syndrome

         11. Uncontrolled or symptomatic secondary hyperparathyroidism

         12. Seizure disorder or receiving anti-epilepsy medication

         13. Known bone marrow fibrosis

         14. Any prior or scheduled organ transplant

         15. Prior treatment with FG-4592 or any hypoxia-inducible factor prolyl hydroxylase
             inhibitor

         16. History of alcohol or drug abuse
Clinical trial NCT01023347 (phase 2, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: paclitaxel (genexol®), paclitaxel loaded polymeric micelle (genexol-pm®)
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological evidence of locally advanced, metastatic or recurrent
             NSCLC (stage IIIB or Iv)

          -  At least one measurable lesion(s) by RECIST criteria

          -  No previous palliative chemotherapy

          -  Age 18 or higher.

          -  ECOG PS 0-2

          -  Life expectancy of at least 3 months.

          -  Adequate hematologic, hepatic, renal function

          -  Adequate bone marrow function (≥ ANC 1,500/ul, ≥ platelet 100,000/ul)

          -  Adequate liver function (≤ Total bilirubin ≤ 1.5 upper normal limit, ≤ AST/ALT x 2.5
             upper normal limit, Alkaline phosphatase ≤ 2.5 upper normal limit)

          -  Adequate renal function (≤ serum creatinine 1.5 mg/dl)

          -  Written informed consent

        Exclusion Criteria:

          -  No prior chemotherapy for NSCLC

          -  Patients with malignancies (other than NSCLC), except for adequately treated
             nonmelanoma skin cancer or in situ carcinoma of the cervix.

          -  Peripheral neuropathy ≥ grade 2 (NCI CTC, version 3.0)

          -  Clinically significant cardiac disease (medically uncontrollable heart disease)

          -  Active infection or other serious medical illness

          -  Contraindication to any drug contained in the chemotherapy regimen

          -  Pregnant or lactating women were excluded.